You're contacting media contact of this press release

Title: BNCM: DELEX Critical Care Products Approved by Philippines FDA

Reno, Nevada, United States, 3rd Oct 2024 - DELEX Pharma offers a wide range of Critical Care products approved by the Philippines’ Food and Drug Administration (FDA). ICU (Intensive Care Unit) is a critical environment for patients facing severe health challenges.DELEX Critical Care ProductsThe Critical Care products are part of DELEX Pharma’s broader portfolio designed to address gaps in the availability of specialized critical care drugs. It is very essential for addressing a wide array of critical care needs, from managing severe pain and hypertension to supporting cardiac function and blood pressure. These products are manufactured under strict compliance with FDA standards, ensuring their quality and effectiveness in critical care management. Details or specific inquiries about these products is available at DELEX Pharma website. DELEX’s Critical Care Product DistributionThe critical care products are strategically placed in drugstore chains nationwide to enhance accessibility. One of the key distribution channels is Mercury Drug, the largest pharmacy chain in the country with thousands of branches, including those in remote areas. This extensive network significantly increases market reach and drives sales growth for the organizations critical care products.DELEX Critical Care Product Registrations with the FDA 1.) Name of Product : GLISENIT (Nitroglycerin)Purpose of Product : Provides relief from anginal chest pain through vasodilationFDA Registration Number : DRP-13372https://verification.fda.gov.ph/ALL_DrugProductslist.php?cmd=search&t=ALL_DrugProducts&psearch=DRP-13372&psearchtype=2.) Name of Product : BETALEX (Labetalol)Purpose of Product : Treats severe hypertension, including hypertensive disorders in pregnancyFDA Registration Nu...

This press release is issued by King Newswire